Moreover, Lund-Iversen et al. [79] reported one G719X/S768I co-mutated case showing PR to erlotinib for more than 14 months, while a long-lasting response to erlotinib with 9-year survival has recently been observed in a patient with NSCLC concomitantly harboring EGFR G719S and a KRAS G12C mutations [95]. Here, KRAS is linked to non-small cell lung carcinoma.